Important notice
Cancer Communications 2021年影响因子突破15分
Cancer Communications 进入2021年中科院期刊分区表医学1区和肿瘤学1区
Cancer Communications 入选中国科协发布的高质量肿瘤学科技期刊T1分级目录
Cancer Communications (CJC) 获评“2019中国最具国际影响力学术期刊”
DLST mutations in pheochromocytoma and paraganglioma cause proteome hyposuccinylation and metabolic remodeling
Sara Mellid, Fernando García, Luis Javier Leandro-García, Alberto Díaz-Talavera, ángel Mario Martínez-Montes, Eduardo Gil, Bruna Calsina, María Monteagudo, Rocío Letón, Juan María Roldán-Romero,
María Santos, Javier Lanillos, Carlos Valdivia, Natalia Martínez-Puente, Javier de Nicolás-Hernández, Scherezade Jiménez, Manuel Pérez-Martínez, Emiliano Honrado, Javier Coloma, Ana Cerezo, Clara María Santiveri, Manel Esteller, Ramón Campos-Olivas, Eduardo Caleiras, Cristina Montero-Conde, Cristina Rodríguez-Antona, Javier Mu?oz, Mercedes Robledo, Alberto Cascón
Risk of cardiovascular disease among parents of children diagnosed with cancer: a population‐based study from Denmark and Sweden
Qianwei Liu, Krisztina D László, Dang Wei, Carsten Obel, Fen Yang, Katja Fall, Unnur Valdimarsdóttir, Maria Feychting, Jiong Li, Fang Fang
Perivascular localized cells commit erythropoiesis in PDGF‐B‐expressing solid tumors
Kayoko Hosaka, Chenchen Wang, Shiyue Zhang, Xue Lv, Takahiro Seki, Yin Zhang, Xu Jing, Jieyu Wu, Qiqiao Du, Xingkang He, Yulong Fan, Xuan Li, Makoto Kondo, Masahito Yoshihara, Hong Qian, Lihong Shi, Ping Zhu, Yuanfu Xu, Yunlong Yang, Tao Cheng, Yihai Cao
Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER‐positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor
Leena Karimi, Carla L. Alves, Mikkel G. Terp, Martina Tuttolomondo, Neil Portman, Sidse Ehmsen, Lene E. Johansen, Martin Bak, Elgene Lim, Henrik J. Ditzel
Antitumoral effects of cannabis in Notch1-mutated T-cell acute lymphoblastic leukemia
Elazar Besser, Anat Gelfand, Gil Moshe Lewitus, Hila Novak-Kotzer, Shiri Procaccia, Paula Berman, Igal Louria-Hayon, Inbar Shreiber-Livne, Yishai Ofran, David Meiri
Knowing nodal Rouviére: the power of human intelligence in toxicity reduction
Annie W. Chan
Real-world outcomes of niraparib treatment in patients with ovarian cancer: a multicenter non‐interventional study in China
Jin Li, Jianhua Yang, Huafeng Shou, Lin Zhang, Xiaohong Huang, Xuedong Tang, Fei Zheng, Fang Liu, Hao Wen, Huijuan Yang, Huaying Wang, Ziting Li, Xiaojun Chen, Xingzhu Ju
Advanced precision modeling reveals divergent responses of hepatocellular carcinoma to combinatorial immunotherapy
Jinping Liu, Lan Cheng, Hilana El-Mekkoussi, Charles-Antoine Assenmacher, Michelle Y. Y. Lee, Danielle R. Jaffe, Kaisha Garvin-Darby, Ashleigh Morgan, Elisabetta Manduchi, Jonathan Schug, Klaus H. Kaestner
High baseline tumor burden‐associated macrophages promote an immunosuppressive microenvironment and reduce the efficacy of immune checkpoint inhibitors through the IGFBP2‐STAT3‐PD‐L1 pathway
Zhaowei Wen, Huiying Sun, Zhihua Zhang, Yannan Zheng, Siting Zheng, Jianping Bin, Yulin Liao, Min Shi, Rui Zhou, Wangjun Liao
Plasma small‐extracellular vesicles enriched in miR‐122‐5p promote disease aggressiveness in pediatric anaplastic large‐cell lymphoma
Damanti Carlotta Caterina, Ferrone Lavinia, Gaffo Enrico, Garbin Anna, Tosato Anna, Contarini Giorgia, Gallingani Ilaria, Angioni Roberta, Molon Barbara, Borile Giulia, Carraro Elisa, Pillon Marta, Scarmozzino Federico, Dei Tos Angelo Paolo, Pizzi Marco, Ciscato Francesco, Rasola Andrea, Biffi Alessandra, Bortoluzzi Stefania, Lovisa Federica, Mussolin Lara
Gastric cancer |
|
Edited by Yun Dai and Li Yan |
This thematic series discusses the molecular classifications of gastric cancer by the Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group (ACRG) as well as the implications in personalized therapeutic choices; discusses the evolution of gastric surgery and presents perspectives on surgical techniques in treating gastric cancer; and reviews current and emerging targeted agents as well as immunotherapies in treating gastric cancer. With these advancements in molecular characterization, surgical intervention, and targeted and immunotherapies, gastric cancer will enter a personalized medicine era in the next 5 years.
|
- - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Tumor angiogenesis |
|
Edited by Francesco Pezzella
|
Forming efficient vasculature network, also known as tumor angiogenesis, is a critical hallmark in tumor development. Explorations on its underlying molecular mechanisms have resulted in several novel anti-cancer drugs. However, the modest survival benefits from anti-angiogenic therapy have forced us to revisit our understanding on tumor angiogenesis. In this special issue, world-leading experts have contributed their critical thoughts to reveal alternative tumor angiogenesis approaches and potential treatment targets.
|
- - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - Lung cancer |
|
 Edited by Lin Yan and Wei Zhang
|
Lung cancer accounts for approximately 21% of worldwide cancer deaths and a staggering 1.6 million new cases are diagnosed every year. In China, lung cancer has become a particularly challenging disease because of air pollution and smoking. This thematic series discusses the proper use of targeted agents in treating lung cancer, reviews the application of biomarkers in clinical management and drug development, and analyzes the unique challenges in developing novel drugs for lung cancer in China.
|
CC adopts ScholarOne Manuscripts
to manage its submissions from Nov.1, 2019
Submission Guidelines
Reference style for
CC is now published by Wiley
© Cancer Communications
651 Dongfeng Road East,Guangzhou 510060, P.R.China
